Abstract
One of the most widely used animal models of Parkinson’s disease (PD) involves injecting 6-hydroxydopamine (6-OHDA) directly into the substantia nigra (SN). Some recent reports speculated that dopaminergic drugs may exert brain antioxidant activity, which could explain some of their protective actions. In this way, the aim of the present study was to examine the effects of low-dose pergolide on memory deficits and brain oxidative stress in a 6-OHDA-induced rat model of PD. Right-unilateral lesions of the SN were produced with 6-OHDA. Two weeks after neurosurgery, pergolide (0.3 mg/kg/day) was injected intraperitoneally in the 6-OHDA + pergolide and sham-operated + pergolide groups, while sham-operated and 6-OHDA alone groups received saline. Radial-8-arm maze and Y-maze were used for memory assessment. We also determined some enzymatic antioxidant defenses like superoxide dismutase or glutathione peroxidase and a lipid peroxidation marker [malondialdehyde (MDA)], from the temporal lobe. A reduced number of working/reference memory errors was observed in 6-OHDA + pergolide group, compared to sham-operated rats. Additionally, post hoc analysis showed significant differences between 6-OHDA and 6-OHDA + pergolide groups in both Y-maze and radial-arm-maze tasks. We also noted a significant decrease of MDA level in the 6-OHDA + pergolide group, compared to sham-operated rats. Significant correlations were also found between behavioral parameters and MDA levels. Our data suggest that pergolide facilitates spatial memory and improves brain oxidative balance, after a 6-OHDA-induced model of PD. This could be useful for further investigations and clinical applications of pergolide.
Similar content being viewed by others
References
Abeliovich A (2010) Parkinson’s disease: mitochondrial damage control. Nature 463:744–745
Avila I, Reilly MP, Sanabria F, Posadas-Sánchez D, Chavez CL, Banerjee N, Killeen P, Castañeda E (2009) Modeling operant behavior in the parkinsonian rat. Behav Brain Res 198:298–305
Berretta N, Freestone PS, Guatteo E, de Castro D, Geracitano R, Bernardi G, Mercuri NB, Lipski J (2005) Acute effects of 6-hydroxydopamine on dopaminergic neurons of the rat substantia nigra pars compacta in vitro. Neurotoxicology 26:869–881
Bisaglia M, Soriano ME, Arduini I, Mammi S, Bubacco L (2010) Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. Biochim Biophys Acta. doi:10.1016/j.bbadis.2010.06.006
Blandini F, Levandis G, Bazzini E, Nappi G, Armentero MT (2007) Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. Eur J Neurosci 25:397–405
Branchi I, D’Andrea I, Armida M, Carnevale D, Ajmone-Cat MA, Pèzzola A, Potenza RL, Morgese MG, Cassano T, Minghetti L, Popoli P, Alleva E (2010) Striatal 6-OHDA lesion in mice: investigating early neurochemical changes underlying Parkinson’s disease. Behav Brain Res 208:137–143
Brusa L, Tiraboschi P, Koch G, Peppe A, Pierantozzi M, Ruggieri S, Stanzione P (2005) Pergolide effect on cognitive functions in early-mild Parkinson’s disease. J Neural Transm 112:231–237
Chalimoniuk M, Stepień A, Strosznajder JB (2004) Pergolide mesylate, a dopaminergic receptor agonist, applied with l-DOPA enhances serum antioxidant enzyme activity in Parkinson disease. Clin Neuropharmacol 27:223–229
Ciobica A, Hritcu L, Artenie V (2009) Changes in the activity of the antioxidant enzymes in 6-hydroxydopamine-induced rat model of Parkinson’s disease. J Neurol Sci 283:282–283
Ciobica A, Hritcu L, Artenie V, Padurariu M (2008) Cognitive disorders in a 6-hydroxydopamine-induced rat model of Parkinson’s disease. Eur Neuropsychopharmacol 18:276
Ciobica A, Hritcu L, Artenie V, Padurariu M (2008) Some aspects of oxidative stress in a rat model of of Parkinson’s disease. Int J Neuropsychopharmacol 11:228–229
Ciobica A, Hritcu L, Artenie V, Padurariu M (2008) The effects of 6-OHDA in the rat brain (memory and oxidative stress processes). Proceedings of the 16th European .Congress of Physical and Rehabilitation Medicine, Brugge, Belgium, 3–6 June 2008. Edizioni Minerva Medica, Turin, pp 132–135
Ciobica A, Hritcu L, Artenie V, Padurariu M, Bild W (2009) A possible correlation between memory and neuronal oxidative stress status in a 6-OHDA model of Parkinson’s disease. Parkinsonism Relat Disord 15:177–178
Ciobica A, Hritcu L, Artenie V, Stoica B, Bild V (2009) Effects of 6-OHDA infusion into the hypothalamic paraventricular nucleus in mediating stress-induced behavioural responses and oxidative damage in rats. Acta Endocrinol 5:425–436
Ciobica A, Hritcu L, Padurariu M, Dobrin R, Bild V (2010) Effects of serotonin depletion on behavior and neuronal oxidative stress status in rat: relevance for anxiety and affective disorders. Adv Med Sci 55(2):89–296
Costa A, Peppe A, Dell’Agnello G, Caltagirone C, Carlesimo GA (2009) Dopamine and cognitive functioning in de novo subjects with Parkinson’s disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 47:1374–1381
da Conceição FS, Ngo-Abdalla S, Houzel JC, Rehen SK (2010) Murine model for Parkinson’s disease: from 6-OH dopamine lesion to behavioral test. J Vis Exp 35. doi:10.3791/1376
De Leonibus E, Managò F, Giordani F, Petrosino F, Lopez S, Oliverio A, Amalric M, Mele A (2009) Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson’s disease. Neuropsychopharmacology 34:729–738
De Leonibus E, Pascucci T, Lopez S, Oliverio A, Amalric M, Mele A (2007) Spatial deficits in a mouse model of Parkinson disease. Psychopharmacology (Berl) 194:517–525
Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci ME, Canteras NS, Da Cunha C (2005) Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson’s disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods 148:78–87
Forster MJ, Dubey A, Dawson KM, Stutts WA, Lal H, Sohal RS (1996) Age-related losses of cognitive function and motor skills in mice are associated with oxidative protein damage in the brain. Proc Natl Acad Sci USA 93:4765–4769
Friedman A, Galazka-Friedman J, Koziorowski D (2009) Iron as a cause of Parkinson disease — a myth or a well established hypothesis? Parkinsonism Relat Disord 15:212–214
Gille G, Rausch WD, Hung ST, Moldzio R, Janetzky B, Hundemer HP, Kolter T, Reichmann H (2002) Pergolide protects dopaminergic neurons in primary culture under stress conditions. J Neural Transm 109:633–643
Gomez-Vargas M, Nishibayashi-Asanuma S, Asanuma M (1998) Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits peroxidation in different regions of the rat brain. Brain Res 790:202–208
Gurzu C, Artenie V, Hritcu L, Ciobica A (2008) Prenatal testosterone improves the spatial learning and memory by protein synthesis in different lobes of the brain in the male and female rat. Cent Eur J Biol 3:39–47
Halliwell B, Gutteridge JMC (2007) Free radical in biology and medicine, 4th edn. Oxford Univ Press, New York
Hanrott K, Gudmunsen L, O’Neill MJ, Wonnacott S (2006) 6-Hydroxydopamine-induced apoptosis is mediated via extracellular autooxidation and caspase 3-dependent activation of protein kinase C delta. J Biol Chem 281:5373–5382
Hritcu L, Ciobica A, Artenie V (2008) Effects of right-unilateral 6-hydroxydopamine infusion-induced memory impairment and oxidative stress: relevance for Parkinson’s disease. Cent Eur J Biol 3:250–257
Hritcu L, Ciobica A, Gorgan L (2009) Nicotine-induced memory impairment by increasing brain oxidative stress. Cent Eur J Biol 4:335–342
Iancu R, Mohapel P, Brundin P, Paul G (2005) Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson’s disease in mice. Behav Brain Res 162:1–10
Karelson E, Bogdanovic N, Garlind A, Winblad B, Zilmer K, Kullisaar T, Vihalemm T, Kairane C, Zilmer M (2001) The cerebrocortical areas in normal brain aging and in Alzheimer’s disease: noticeable differences in the lipid peroxidation level and in antioxidant defense. Neurochem Res 26:353–361
Kimberg DY, D’Esposito M (2003) Cognitive effects of the dopamine receptor agonist pergolide. Neuropsychologia 41:1020–1027
Küçükatay V, Balkan S, Yaraş N, Yargiçoğlu P, Ağar A (2002) The effect of pergolide on cognitive performance of young and middle-aged rats. Int J Neurosci 112:1027–1036
Le WD, Jankovic J (2001) Are dopamine receptor agonists neuroprotective in Parkinson’s disease? Drugs Aging 18:389–396
Levin ED (1995) Pergolide interactions with nicotine and pilocarpine in rats on the radial-arm maze. Pharmacol Biochem Behav 52:837–840
Mehta MA, Riedel WJ (2006) Dopaminergic enhancement of cognitive function. Curr Pharm Des 12:2487–2500
Mei J, Niu C (2010) Alterations of Hrd1 expression in various encephalic regional neurons in 6-OHDA model of Parkinson’s disease. Neurosci Lett 474:63–68
Micale V, Incognito T, Ignoto A, Rampello L, Spartà M, Drago F (2006) Dopaminergic drugs may counteract behavioral and biochemical changes induced by models of brain injury. Eur Neuropsychopharmacol 16:195–203
Navarro A, Sánchez Del Pino MJ, Gómez C, Peralta JL, Boveris A (2002) Behavioral dysfunction, brain oxidative stress, and impaired mitochondrial electron transfer in aging mice. Am J Physiol Regul Integr Comp Physiol 282:985–992
Ono S, Hirai K, Tokuda E (2009) Effects of pergolide mesilate on metallothionein mRNAs expression in a mouse model for Parkinson disease. Biol Pharm Bull 32:1813–1817
Opacka-Juffry J, Wilson AW, Blunt SB (1998) Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxyldopamine in rat striatum. Brain Res 810:27–33
Ozer F, Tiras R, Cetin S, Ozturk O, Aydemir T, Ozben S, Meral H, Kizkin S, Bader H, Ozben B (2009) Valvular heart disease in patients with Parkinson’s disease treated with pergolide, levodopa or both. J Clin Neurosci 16:83–87
Padurariu M, Ciobica A, Dobrin I, Stefanescu C (2010) Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 479:317–320
Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C (2010) Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett 469:6–10
Paxinos G, Watson C (2006) The rat brain in stereotaxic coordinates, 6th edn. Academic, San Diego
Possin KL, Filoteo JV, Song DD, Salmon DP (2008) Spatial and object working memory deficits in Parkinson’s disease are due to impairment in different underlying processes. Neuropsychology 22:585–595
Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29–38
Schapira AH, Tolosa E (2010) Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 6:309–317
Seet RC, Lee CY, Lim EC, Tan JJ, Quek AM, Chong WL, Looi WF, Huang SH, Wang H, Chan YH, Halliwell B (2010) Oxidative damage in Parkinson disease: measurement using accurate biomarkers. Free Radic Biol Med 48:560–566
Shukitt-Hale B (1999) The effects of aging and oxidative stress on psychomotor and cognitive behavior. Age 22:9–17
Shukitt-Hale B, Denisova NA, Strain JG, Joseph JA (1997) Psychomotor effects of dopamine infusion under decreased glutathione conditions. Free Radic Biol Med 23:412–418
Shukitt-Hale B, Erat SA, Joseph JA (1998) Spatial learning and memory deficits induced by dopamine administration with decreased glutathione. Free Radic Biol Med 24:1149–1158
Spencer Smith T, Parker W, Bennett J (1994) Levodopa increases nigral production of hydroxyl radicals in vivo: potential levodopa toxicity? Neuroreport 5:1009–10011
Uberti D, Carsana T, Francisconi S, Ferrari Toninelli G, Canonico PL, Memo M (2004) A novel mechanism for pergolide-induced neuroprotection: inhibition of NF-kappaB nuclear translocation. Biochem Pharmacol 67:1743–1750
Uberti D, Piccioni L, Colzi A, Bravi D, Canonico PL, Memo M (2002) Pergolide protects SH-SY5Y cells against neurodegeneration induced by H(2)O(2). Eur J Pharmacol 434:17–20
Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D (2004) Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179–1183
Wypijewska A, Galazka-Friedman J, Bauminger ER, Wszolek ZK, Schweitzer KJ, Dickson DW, Jaklewicz A, Elbaum D, Friedman A (2010) Iron and reactive oxygen species activity in parkinsonian substantia nigra. Parkinsonism Relat Disord 16:329–333
Acknowledgments
This work was supported by a POSDRU grant /89/1.5/S/49944, “Developing the innovation capacity and improving the impact of research through post-doctoral programs” Alexandru Ioan Cuza University, Iasi. The authors would also like to show their gratitude to the reviewer of this paper which significantly improved the value of the presented data by adding very important insights, comments, and suggestions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ciobica, A., Olteanu, Z., Padurariu, M. et al. The effects of pergolide on memory and oxidative stress in a rat model of Parkinson’s disease. J Physiol Biochem 68, 59–69 (2012). https://doi.org/10.1007/s13105-011-0119-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13105-011-0119-x